Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.
Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, Hirakawa A, Shimizu S, Nakamura T, Katsuno M. Yamada S, et al. Among authors: shimizu s. Ann Clin Transl Neurol. 2022 Nov;9(11):1702-1714. doi: 10.1002/acn3.51667. Epub 2022 Oct 8. Ann Clin Transl Neurol. 2022. PMID: 36208052 Free PMC article. Clinical Trial.
Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol.
Shimizu S, Yamamoto T, Nakayama S, Hirakawa A, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Shimizu S, et al. BMC Urol. 2017 Sep 25;17(1):89. doi: 10.1186/s12894-017-0282-7. BMC Urol. 2017. PMID: 28946874 Free PMC article. Clinical Trial.
Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol.
Shimizu S, Tsuchiya S, Hirakawa A, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H. Shimizu S, et al. BMC Oral Health. 2019 Apr 30;19(1):69. doi: 10.1186/s12903-019-0753-1. BMC Oral Health. 2019. PMID: 31039763 Free PMC article. Clinical Trial.
Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.
Iida M, Sahashi K, Kondo N, Nakatsuji H, Tohnai G, Tsutsumi Y, Noda S, Murakami A, Onodera K, Okada Y, Nakatochi M, Tsukagoshi Okabe Y, Shimizu S, Mizuno M, Adachi H, Okano H, Sobue G, Katsuno M. Iida M, et al. Among authors: shimizu s. Nat Commun. 2019 Sep 19;10(1):4262. doi: 10.1038/s41467-019-12282-7. Nat Commun. 2019. PMID: 31537808 Free PMC article.
Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.
Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, Koike H, Kaida K, Koga M, Kanda T, Ogata H, Kira JI, Mori M, Kuwabara S, Katsuno M. Shimizu S, et al. JMIR Res Protoc. 2020 Apr 1;9(4):e17117. doi: 10.2196/17117. JMIR Res Protoc. 2020. PMID: 32234705 Free PMC article.
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Mizutani Y, Iida T, Ohno E, Ishikawa T, Kinoshita F, Kuwatsuka Y, Imai M, Shimizu S, Tsuruta T, Enomoto A, Kawashima H, Fujishiro M. Mizutani Y, et al. Among authors: shimizu s. BMC Cancer. 2022 Feb 24;22(1):205. doi: 10.1186/s12885-022-09272-2. BMC Cancer. 2022. PMID: 35209871 Free PMC article.
Influence of background characteristics in responders of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence.
Yamanishi T, Ishizuka O, Shimizu S, Kobayashi Y, Kinoshita F, Yamamoto T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Kuwatsuka Y, Mizuno M, Gotoh M. Yamanishi T, et al. Among authors: shimizu s. Low Urin Tract Symptoms. 2022 Jul;14(4):273-280. doi: 10.1111/luts.12433. Epub 2022 Feb 25. Low Urin Tract Symptoms. 2022. PMID: 35218150
Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.
Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Matsuyama N, et al. Among authors: shimizu s. BMJ Open. 2022 Apr 26;12(4):e057073. doi: 10.1136/bmjopen-2021-057073. BMJ Open. 2022. PMID: 35473726 Free PMC article. Clinical Trial.
Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy.
Tanaka A, Furuhashi K, Fujieda K, Maeda K, Saito S, Mimura T, Saka Y, Naruse T, Ishimoto T, Kosugi T, Kinoshita F, Kuwatsuka Y, Shimizu S, Nakai Y, Maruyama S. Tanaka A, et al. Among authors: shimizu s. Front Med (Lausanne). 2022 May 27;9:883168. doi: 10.3389/fmed.2022.883168. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35692547 Free PMC article.
4,532 results